Pfizer Inc. $PFE Shares Sold by ICONIQ Capital LLC

ICONIQ Capital LLC trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 12.7% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 15,447 shares of the biopharmaceutical company’s stock after selling 2,256 shares during the period. ICONIQ Capital LLC’s holdings in Pfizer were worth $391,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. William B. Walkup & Associates Inc. increased its holdings in shares of Pfizer by 1.2% in the 4th quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company’s stock worth $1,044,000 after acquiring an additional 454 shares during the period. Members Trust Co increased its holdings in shares of Pfizer by 2.1% in the 1st quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company’s stock worth $587,000 after acquiring an additional 467 shares during the period. Sutton Place Investors LLC increased its holdings in shares of Pfizer by 5.6% in the 1st quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company’s stock worth $224,000 after acquiring an additional 472 shares during the period. Bellevue Group AG increased its holdings in shares of Pfizer by 0.3% in the 4th quarter. Bellevue Group AG now owns 141,560 shares of the biopharmaceutical company’s stock worth $3,756,000 after acquiring an additional 485 shares during the period. Finally, MSH Capital Advisors LLC increased its holdings in shares of Pfizer by 1.4% in the 1st quarter. MSH Capital Advisors LLC now owns 34,585 shares of the biopharmaceutical company’s stock worth $876,000 after acquiring an additional 485 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Bank of America increased their price objective on shares of Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Berenberg Bank decreased their target price on shares of Pfizer from $28.00 to $25.00 and set a “hold” rating for the company in a research report on Thursday, May 29th. Redburn Atlantic decreased their target price on shares of Pfizer from $29.00 to $27.00 and set a “neutral” rating for the company in a research report on Wednesday, April 30th. HSBC decreased their target price on shares of Pfizer from $27.00 to $26.00 and set a “buy” rating for the company in a research report on Monday, May 19th. Finally, Morgan Stanley increased their target price on shares of Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $28.12.

Pfizer Trading Up 0.3%

Pfizer stock opened at $25.8250 on Monday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The firm has a market cap of $146.83 billion, a price-to-earnings ratio of 13.74, a price-to-earnings-growth ratio of 0.92 and a beta of 0.52. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The firm’s 50 day moving average price is $24.70 and its two-hundred day moving average price is $24.39.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.7%. The ex-dividend date is Friday, July 25th. Pfizer’s dividend payout ratio (DPR) is presently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.